Breast cancer-on-chip for patient-specific efficacy and safety testing of CAR-T cells

• DOI: 10.1016/j.stem.2024.04.018
• Publication Date: 2024-05-15T14:48:25Z
• Authors: Tengku Ibrahim Ma...; Claudia Teufel; Madalena Cipriano; Julia Roosz; Lisa Lazarevski; Francijna E. van ...; Lukas Scheller; Valeria Orlova; André Koch; Michael Hudecek; Miriam Alb; Peter Loskill

Physiologically relevant human models that recapitulate the challenges of solid tumors and tumor microenvironment (TME) are highly desired in chimeric antigen receptor (CAR)-T cell field. We developed a breast cancer-on-chip model with an integrated endothelial barrier enables transmigration perfused immune cells, their infiltration into tumor, concomitant monitoring cytokine release during culture over period up to 8 days. Here, we exemplified its use for investigating CAR-T efficacy ability control reaction pharmacological on/off switch. Additionally, primary cancer organoids study patient-specific efficacy. The modular architecture our tumor-on-chip paves way studying role other types TME thus provides potential broad application bench-to-bedside translation as well acceleration preclinical development products.